Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | Director | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 8,583 |
Reported balance
After 2021-02-26 transaction · row 1
1 source rowRow 1 · 2021-02-26 · Grant · Acquired 226 · Balance 8,583 |
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | IndirectBy IRA | 12 |
Reported balance
Holding disclosure · report date 2021-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DAVITA INC.
Report date June 11, 2020 · Filed June 15, 2020
Section 16 reporting ended · disclosed 2020-06-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,234 |
Reported balance
After 2020-06-11 transaction · row 1
1 source rowRow 1 · 2020-06-11 · Grant · Acquired 273 · Balance 16,234 |
Express Scripts Holding Co.
Report date December 20, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 18,917.674 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. |
| Common StockSEC Table I · non-derivative | IndirectBy IRA | 0 |
Reported balance
After 2018-12-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-12-20 · Disposition to issuer · Disposed 52 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.53 · Expires 2019-05-30 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-20 · Disposition to issuer · Disposed 6,870 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.58 · Expires 2020-05-09 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-20 · Disposition to issuer · Disposed 5,872 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.05 · Expires 2021-05-07 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-20 · Disposition to issuer · Disposed 6,402 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.08 · Expires 2025-05-06 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-20 · Disposition to issuer · Disposed 5,604 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.74 · Expires 2026-05-04 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-20 · Disposition to issuer · Disposed 7,032 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.66 · Expires 2027-05-11 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-20 · Disposition to issuer · Disposed 8,006 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement.
F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2021 Filed Mar 2, 2021 17:30 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 226 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004296 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,583 Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 17:33 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 227 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-014156 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,357 Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 17:37 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 267 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-011224 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,130 Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:43 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-20-000144 · wf-form4_159226099264163.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,234 Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:21 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 4,662 | $0.00 Strike: $81.51 | $0.00 |
DisclosureSEC source: 0000927066-20-000133 · wf-form4_159182767735962.xml · derivative · entry 4 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,662 shares Expires 2020-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Stock Appreciation Rights were granted on June 16, 2015, and 100% vested on June 16, 2016. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:21 UTC | DAVITA INC. DVA · Entity 3482 | SaleCommon Stock | 357 | $86.79 | $30,983.49 |
DisclosureSEC source: 0000927066-20-000133 · wf-form4_159182767735962.xml · nonDerivative · entry 3 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,961 F1 · price: Represents the weighted average sale price of $86.7885. The range of prices for the sale of these shares was $86.7701 - $86.8250 rounded to the nearest ten-thousandths. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:21 UTC | DAVITA INC. DVA · Entity 3482 | Disposition to issuerCommon Stock | 4,305 | $88.28 | $380,045.40 |
DisclosureSEC source: 0000927066-20-000133 · wf-form4_159182767735962.xml · nonDerivative · entry 2 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,318 Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:21 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionCommon Stock | 4,662 | $81.51 | $379,999.62 |
DisclosureSEC source: 0000927066-20-000133 · wf-form4_159182767735962.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 17:15 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 240 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-008490 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,863 Read SEC document |
| May 15, 2020 Filed May 20, 2020 01:18 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 599 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-20-000104 · wf-form4_158993749152852.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,961 Read SEC document |
| May 05, 2020 Filed May 7, 2020 17:09 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,819 | $0.00 Strike: $128.24 | $0.00 |
DisclosureSEC source: 0001225208-20-007213 · doc4.xml · derivative · entry 4 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 2,819 shares Expires 2020-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were executed in anticipation of the option expiration date of May 9, 2020. F2 · derivative.exercise_date: These stock options were granted on May 9, 2013 and vested in three equal installments on May 1, 2014, May 1, 2015 and May 1, 2016. Read SEC document |
| May 05, 2020 Filed May 7, 2020 17:09 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 2,819 | $192.07 | $541,445.33 |
DisclosureSEC source: 0001225208-20-007213 · doc4.xml · nonDerivative · entry 2 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,623 F1 · kind: These transactions were executed in anticipation of the option expiration date of May 9, 2020. Read SEC document |
| May 05, 2020 Filed May 7, 2020 17:09 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 2,819 | $128.24 | $361,503.77 |
DisclosureSEC source: 0001225208-20-007213 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,442 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were executed in anticipation of the option expiration date of May 9, 2020. Read SEC document |
| March 15, 2020 Filed Mar 17, 2020 23:55 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-20-000046 · wf-form4_158448930274722.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,362 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 17:07 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 259 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004186 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,623 Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 19:41 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015094 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,364 Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 23:24 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 671 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000190 · wf-form4_157420583621511.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,737 Read SEC document |
| August 30, 2019 Filed Sep 4, 2019 17:34 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 308 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-012171 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 22:20 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 814 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000155 · wf-form4_156599403140555.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,066 Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 18:23 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008744 · doc4.xml · nonDerivative · entry 3 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,819 Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 18:23 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,298 | $0.00 Strike: $109.39 | $0.00 |
DisclosureSEC source: 0001225208-19-008744 · doc4.xml · derivative · entry 5 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 3,298 shares Expires 2019-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Represents options that were automatically exercised immediately prior to their expiration. F3 · derivative.exercise_date: Stock options previously awarded pursuant to Express Scripts, Inc. 2011 Long-Term Incentive Plan. Options vested in three equal annual installments on May 1, 2013, May 1, 2014, and May 1, 2015. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 18:23 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,438 | $147.99 | $360,799.62 |
DisclosureSEC source: 0001225208-19-008744 · doc4.xml · nonDerivative · entry 2 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,499 F1 · shares: Represents shares tendered to Company to cover payment of exercise price due upon exercise of stock options. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 18:23 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 3,298 | $109.39 | $360,774.82 |
DisclosureSEC source: 0001225208-19-008744 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2019 Filed May 17, 2019 23:23 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 946 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000074 · wf-form4_155813539909483.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,252 Read SEC document |
| April 01, 2019 Filed Apr 4, 2019 00:29 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 437 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000041 · wf-form4_155433778144560.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,306 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 18:39 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 272 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004408 · doc4.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,639 Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 00:13 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 462 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-19-000012 · wf-form4_154656081579852.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,869 Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · nonDerivative · entry 2 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Read SEC document |
| December 21, 2018 Filed Feb 8, 2019 17:56 UTC Amendment | Cigna Group CI · Entity 550 | GrantCommon Stock, $0.01 Par Value | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-002851 · doc1.xml · nonDerivative · entry 2 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,367 Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:41 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 8,006 | $0.00 Strike: $60.66 | $0.00 |
DisclosureSEC source: 0000950138-18-000705 · edgar.xml · derivative · entry 8 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 8,006 shares Expires 2027-05-11 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:41 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 7,032 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0000950138-18-000705 · edgar.xml · derivative · entry 7 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 7,032 shares Expires 2026-05-04 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:41 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 5,604 | $0.00 Strike: $84.08 | $0.00 |
DisclosureSEC source: 0000950138-18-000705 · edgar.xml · derivative · entry 6 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 5,604 shares Expires 2025-05-06 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:41 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 6,402 | $0.00 Strike: $67.05 | $0.00 |
DisclosureSEC source: 0000950138-18-000705 · edgar.xml · derivative · entry 5 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 6,402 shares Expires 2021-05-07 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:41 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 5,872 | $0.00 Strike: $61.58 | $0.00 |
DisclosureSEC source: 0000950138-18-000705 · edgar.xml · derivative · entry 4 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 5,872 shares Expires 2020-05-09 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:41 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerNon-Qualified Stock Option (Right to Buy) · Derivative | 6,870 | $0.00 Strike: $52.53 | $0.00 |
DisclosureSEC source: 0000950138-18-000705 · edgar.xml · derivative · entry 3 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Express Scripts Holding Company Common Stock · 6,870 shares Expires 2019-05-30 F3 · price: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:41 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerCommon Stock | 52 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-18-000705 · edgar.xml · nonDerivative · entry 2 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 0 F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. Read SEC document |
| December 20, 2018 Filed Dec 21, 2018 17:41 UTC | Express Scripts Holding Co. ESRX · Entity 161583 | Disposition to issuerCommon Stock | 18,917.674 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-18-000705 · edgar.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. F1 · price: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,844 | Not disclosed Strike: $126.32 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 9 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,844 Underlying: Common Stock, $0.01 Par Value · 3,844 shares Expires 2027-05-11 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,376 | Not disclosed Strike: $151.48 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 8 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,376 Underlying: Common Stock, $0.01 Par Value · 3,376 shares Expires 2026-05-04 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,691 | Not disclosed Strike: $175.09 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 7 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,691 Underlying: Common Stock, $0.01 Par Value · 2,691 shares Expires 2025-05-06 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,074 | Not disclosed Strike: $139.63 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 6 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,074 Underlying: Common Stock, $0.01 Par Value · 3,074 shares Expires 2021-05-07 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,819 | Not disclosed Strike: $128.24 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 5 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,819 Underlying: Common Stock, $0.01 Par Value · 2,819 shares Expires 2020-05-09 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,298 | Not disclosed Strike: $109.39 | Not disclosed |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · derivative · entry 4 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,298 Underlying: Common Stock, $0.01 Par Value · 3,298 shares Expires 2019-05-30 F4 · derivative.exercise_price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In connection with the Merger, each stock option of Express Scripts outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option, with the same terms and conditions, to purchase the number shares of New Cigna Common Stock as determined in accordance with the terms of the Merger Agreement, with an exercise price determined in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $0.01 Par Value | 12 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · nonDerivative · entry 3 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 12 F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 19:20 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $0.01 Par Value | 4,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-008711 · doc1.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,604 F1 · kind: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Represents shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document |
| December 20, 2018 Filed Feb 8, 2019 17:56 UTC Amendment | Cigna Group CI · Entity 550 | GrantCommon Stock, $0.01 Par Value | 5,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-002851 · doc1.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,166 F1 · kind: Represents 1,866 shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") and 3,300 Deferred Stock Units of New Cigna acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. Pursuant to the Merger Agreement, upon closing of the Merger, each Express Scripts deferred stock unit was converted into a deferred stock unit relating to the common stock of New Cigna in accordance with the equity award exchange ratio set forth in the merger agreement. F3 · shares: Prior to the Merger, the reporting person held Express Scripts common stock, restricted stock units and deferred stock units. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement and each deferred stock unit was converted into a deferred stock unit relating to the common stock of New Cigna in accordance with the equity award exchange ratio set forth in the Merger Agreement. The Form 4 filed December 26, 2018 inadvertently included the conversion of those restricted stock units and deferred stock units into shares of New Cigna Common Stock based on the merger consideration exchange ratio. This amendment is being filed to correct that administrative error. F1 · price: Represents 1,866 shares of Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna") and 3,300 Deferred Stock Units of New Cigna acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · price: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. In the Merger, each share of Express Scripts common stock, par value $0.01 per share ("ESRX Common Stock"), was exchanged for (1) 0.2434 of a share, par value $0.01 per share, of New Cigna ("New Cigna Common Stock") and (2) the right to receive $48.75 in cash, without interest, subject to applicable withholding taxes. Pursuant to the Merger Agreement, upon closing of the Merger, each Express Scripts deferred stock unit was converted into a deferred stock unit relating to the common stock of New Cigna in accordance with the equity award exchange ratio set forth in the merger agreement. F3 · balance_after: Prior to the Merger, the reporting person held Express Scripts common stock, restricted stock units and deferred stock units. Each restricted stock unit was converted into a right to receive a cash payment in accordance with the payment ratio set forth in the Merger Agreement and each deferred stock unit was converted into a deferred stock unit relating to the common stock of New Cigna in accordance with the equity award exchange ratio set forth in the Merger Agreement. The Form 4 filed December 26, 2018 inadvertently included the conversion of those restricted stock units and deferred stock units into shares of New Cigna Common Stock based on the merger consideration exchange ratio. This amendment is being filed to correct that administrative error. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 17:56 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 332 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-18-000180 · wf-form4_153850297772157.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,407 Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 23:56 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 342 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-18-000151 · wf-form4_153066219433479.xml · nonDerivative · entry 1 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,075 Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:52 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 36,000 | $0.00 Strike: $65.08 | $0.00 |
DisclosureSEC source: 0000927066-18-000114 · wf-form4_152720230023309.xml · derivative · entry 4 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2018-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2018 Filed May 24, 2018 22:52 UTC | DAVITA INC. DVA · Entity 3482 | SaleCommon Stock | 1,505 | $68.22 | $102,676.97 |
DisclosureSEC source: 0000927066-18-000114 · wf-form4_152720230023309.xml · nonDerivative · entry 3 ROPER WILLIAM L · CIK 0001087960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,733 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.